Enter your terms above and click the 'Search' button.

Showing articles 0 to 8 of 8 Filter Applied: cost effectiveness (Click to remove) Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics Arch Neurol 56:1079-1084, Rudick,R.A., 1999 Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis BMJ 319:1529-1533, Forbes,R.B.,et al, 1999 HIV-Protease Inhibitors NEJM 338:1281-1292, Flexner,C., 1998 HIV-1 Protease Inhibitors JAMA 227:145-149, Deeks,S.J.,et al, 1997 HIV Infection-1 BMJ 314:487-491, 579-5831997., Cohn,J.A., 1997 The Quality-of-Life Effects of Interferon Beta-1b in MS Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997 Interferon Beta in Multiple Sclerosis BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996 The Impact of New Pharmaceutical Agents on the Cost of Neurologic Care Neurol 45:569-572, Gunderson,C.H., 1995 Showing articles 0 to 8 of 8